Question to the Department of Health and Social Care:

To ask Her Majesty's Government when Ronapreve will be available for (1) immunocompromised patients unlikely to mount a vaccine response, and (2) patients at higher risk of poorer COVID-19 outcomes prior to hospitalisation.

On 20 August 2021, the Medicines and Healthcare products Regulatory Agency approved Ronapreve (casirivimab and imdevimab) as the first monoclonal antibody combination product indicated for use in the prevention and treatment of acute COVID-19 infection. A new NHS interim clinical policy will provide access for the most vulnerable non-hospitalised patients in the community with early-stage disease from 16 December, including the immunocompromised and those patients at higher risk of poorer COVID-19 outcomes.

The current supply of Ronapreve is limited globally, therefore the clinical policy prioritises the most vulnerable patients for whom this treatment will provide the most benefit, supported by clinical evidence.